



## REGULATED INFORMATION

### **PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE “TRANSPARENCY LAW”)**

**GHENT, Belgium, 25 November 2013** – **Ablynx [Euronext Brussels: ABLX]**, today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted to trading on a regulated market (the “Transparency Law”), that it received a notification of shareholdings from Biotech Value Fund Partners LP (BVF Partners LP), Biotech Value Fund Inc (BVF Inc) and Sofinnova Partners SAS.

Biotech Value Fund Partners LP and Biotech Value Fund Inc notified that they have exceeded the 5% threshold and now hold 2,554,524 Ablynx shares, which represent 5.23% (compared to a 3.49% holding at 30 September 2013) of the current 48,827,645 outstanding shares of Ablynx.

Sofinnova Partners SAS notified that they have dropped below the 3% threshold and now have sold their complete stake in Ablynx.

As the general partner of Biotechnology Value Fund LP (BVF) and Biotech Value Fund II LP (BVF 2), BVF Partners LP (Partners) is authorised to exercise the voting rights owned directly by BVF and BVF 2. As the advisor to Investment 10, LLC (INV 10) and the manager of BVF Investments, LLC (BVF LLC) BVF Partners is authorised to exercise the voting rights owned directly by INV10 and BVF LLC. As the general partner of BVF Partners, BVF Inc has management authority over BVF Partners. As the President of BVF Inc, Mr Lampert has management authority over BVF Inc.

Full versions of all transparency notifications are available on the website of Ablynx, under the section [Investors](#).

#### **About Ablynx**

[Ablynx](#) is a biopharmaceutical company engaged in the discovery and development of [Nanobodies®](#), a novel class of therapeutic proteins based on single-domain antibody fragments, for a range of serious human diseases, including inflammation, haematology, oncology and pulmonary disease. Today, the Company has approximately [30 programmes in the pipeline](#) and seven Nanobodies at clinical development stage. Ablynx has on-going research collaborations and significant partnerships with major pharmaceutical companies including AbbVie, Boehringer Ingelheim, Eddingpharm, Merck & Co, Merck Serono and Novartis. The Company is headquartered in Ghent, Belgium.

More information can be found on [www.ablynx.com](http://www.ablynx.com).

**For more information, please contact:**

**Ablynx:**

Dr Edwin Moses

CEO

t: +32 (0)9 262 00 07

m: +44 (0)7771 954 193 /

+32 (0)473 39 50 68

e: [edwin.moses@ablynx.com](mailto:edwin.moses@ablynx.com)


Marieke Vermeersch

Associate Director Investor Relations

t: +32 (0)9 262 00 82

m: +32 (0)479 49 06 03

e: [marieke.vermeersch@ablynx.com](mailto:marieke.vermeersch@ablynx.com)

 @AblynxABLX

**Ablynx media relations Consilium Strategic Communications:**

Mary-Jane Elliott, Amber Bielecka, Lindsey Neville

t: +44 207 920 2345

e: [ablynx@consilium-comms.com](mailto:ablynx@consilium-comms.com)

*Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company or, as appropriate, the Company directors' current expectations and projections about future events. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, the Company expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based. Neither the Company nor its advisers or representatives nor any of its parent or subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.*